A REVIEW ARTICLE TO DEVELOP SUSTAIN RELEASE RIVAROXABAN FORMULATION

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto.[1] In the United States, it is marketed by Janssen Pharmaceutical.[2] It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last 8?12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible